封面
市场调查报告书
商品编码
1179902

2023-2030全球镇痛药市场

Global Pain Relief Medication Market - 2023-2030

出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

疼痛是由于组织损伤或疾病而产生的一种不舒服的感觉。 多种情况都会引发痛苦,包括腹部溃疡、硬化、骨关节炎、慢性关节炎、糖尿病性神经病变和癌症。 感觉性疼痛可分为长期慢性疼痛和持续数月、数週或数天的短期急性疼痛。 另一方面,慢性疼痛会持续多年。

市场动态

在预测期内,为改善患者生活质量而对止痛药的需求不断增加,正在推动全球止痛药市场的增长。

对止痛药不断增长的需求正在推动全球市场的增长。

镇痛剂可缓解术后疼痛、严重身体损伤或癌症疼痛等情况下的极度疼痛。 它也用于其他长期疼痛。 术后疼痛、身体创伤以及慢性非传染性疾病(如关节炎和癌症)的增加正在创造对止痛药的需求。 例如,据世界卫生组织称,每年有超过数百万人遭受非致命伤害,导致住院、全科医生护理、急诊室和急症护理医院就诊,而且通常是暂时性伤害。或遭受永久性伤害失能。 此外,国际癌症研究机构(WHO)估计,2020 年全球约有 19,292,789 例不同类型癌症的新病例。 同样,根据全球类风湿性关节炎网络,到 2021 年将有大约 3.5 亿人患有关节炎。 此外,美国国立卫生研究院指出,超过 75% 的接受手术的患者会经历急性术后疼痛,其严重程度可能为中度至重度。

此外,全球手术数量的增加也在扩大全球镇痛剂市场。 例如,根据欧洲核心健康指标 (ECHI),白内障手术和剖腹产是欧盟医院最常进行的两种手术/程序。 2020 年,欧盟成员国共进行了 366 万次白内障手术。 与此同时,2020 年欧盟至少进行了 112 万例剖腹产手术。

其他止痛疗法的可用性和采用仍然是全球市场增长的主要障碍。

但是,其他使用低压电流来治疗疼痛的镇痛疗法,例如经皮神经电刺激 (TENS) 疗法,已经可用并被引入。 此外,2021 年 1 月,波士顿科学公司将推出 WaveWriter Alpha,这是一种脊髓刺激器 (SCS) 系统组合,包含用于缓解个性化疼痛的治疗选项。

COVID-19 影响分析

COVID-19 大流行对全球止痛药市场产生了重大影响。 2019 年冠状病毒病 (COVID-19) 流行期间的慢性疼痛管理一直具有挑战性,尤其是越来越多的证据表明 COVID-19 感染与肌痛、参照痛和广泛痛觉过敏有关。。 非阿片类镇痛药,单独使用或与非甾体抗炎药 (NSAIDs) 联合使用,作为多模式镇痛的一部分来控制轻度至中度疼痛,可能与发烧、头痛、急性或慢性疼痛有关。它被安全地用于缓解COVID-19 的症状,如疼痛,导致对止痛药的需求增加,这对市场增长产生了积极影响。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 对止痛药的需求不断增加
      • 老年人口增加
    • 约束因素
      • 其他替代方案的可用性
    • 商机
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第7章给药途径

  • 口服剂
  • 注射
  • 外部代理

第 8 章按类型

  • 急性期
  • 慢性期

第 9 章分销渠道

  • 医院药房
  • 零售药房
  • 在线药店

第10章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第11章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准

第12章公司简介

  • 梯瓦製药工业有限公司
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Bayer AG
  • Sanofi S.A.
  • GlaxoSmithKline plc.
  • Bristo-Meyers Squibb and Company
  • Mylan N.V.
  • Merck & Co.
  • Cardinal Health Inc.

第13章 DataM

简介目录
Product Code: DMPH6131

Market Overview

The global pain relief medication size was valued at US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period (2023-2030).

Pain is a troubling sensation developed because of tissue injury or disease. Various conditions can induce distress, like abdominal ulcers, sclerosis, osteoarthritis, chronic arthritis, diabetic neuropathy, and cancer. Based on the duration of pain, sensation pain is of two types chronic, lasting for the long term, and acute pain for the short term, which can last for months, weeks, or days. In contrast, chronic pain lasts for years.

Market Dynamics

The rising need for pain-relieving medication to increase the patient quality of life is boosting the global pain-relief medication market growth during the forecast period.

The growing demand for pain-relieving medication is fueling the market growth globally.

Pain Relief Medications alleviate extreme pain in conditions such as post-surgery pain, a serious physical injury, or pain from cancer. They are also used for other types of long-standing pain. The growing number of postoperative pains, physical traumas and chronic non-communicable diseases such as arthritis and cancer are creating the demand for Pain Relief Medication. For instance, according to the WHO, more than millions suffer non-fatal injuries each year, which lead to hospitalizations or treatment by general practitioners or emergency department and acute care visits and often result in temporary or permanent disability. Also, the International Agency for Research on Cancer WHO assessed there were about 19292789 new cases of different types of cancer globally in 2020. Similarly, according to the Global Rheumatoid Arthritis Network, approximately 350 million people lived with arthritis in 2021. Additionally, the NIH states that over 75% of the patients who have undergone surgery experience acute postoperative pain, which might be medium to high in severity.

Furthermore, the increasing number of surgeries performed globally also expands the global pain relief medication market. For instance, according to the European core health indicators (ECHI), the two most common surgical operations and procedures performed in EU hospitals were cataract surgery and cesarean sections. Cataract surgery was conducted 3.66 million times in 2020 across the EU Member States. At the same time, the cesarean section procedure was performed at least 1.12 million times in the EU in 2020.

The availability and introduction of other pain-relieving treatments is a major hurdle in the market's global growth.

However, the availability and introduction of other pain relieving treatments, such as Transcutaneous Electrical Nerve Stimulation (TENS) therapy, involves using low-voltage electric currents to treat pain. Furthermore, in January 2021, Boston Scientific Corporation introduced the WaveWriter Alpha, a portfolio of Spinal Cord Stimulator (SCS) systems that incorporate treatment choices for personalized pain relief.

COVID-19 Impact Analysis

The COVID-19 pandemic has greatly impacted the global pain relief medication market. Chronic pain management during the coronavirus disease 2019 (COVID-19) pandemic was difficult, particularly with rising proof that COVID-19 infection is associated with myalgias, referred pain, and widespread hyperalgesia. Non-Opioid Analgesic medication used alone or in combination with non-steroidal anti-inflammatory drugs (NSAIDs) in addressing mild-to-moderate pain as part of multimodal analgesia, also be utilized safely to relieve symptoms of COVID-19, like fever, headache, and acute or chronic pain, which led to increased demand for pain relief medication and positively impacted the market growth.

Segment Analysis

The chronic pain type is predicted to hold a large share of the global pain relief medication market during the forecast period (2022-2029).

The chronic pain type is expected to hold most of the market share during the forecasted period. According to the Johns Hopkins Hospital, Chronic pain is long-standing pain that lasts beyond the normal healing period or surfaces along with a chronic health condition, like arthritis, Cancer pain, migraines, cluster headaches and others. Chronic pain may be "appearing" and "disappearing" or continuous. The U.S. spends $3.5 trillion annually on health care, with 90% of that going to chronic conditions, including chronic pain. Moreover, according to an article by The Lancet, Chronic pain exerts an immense individual and financial hindrance, impacting over 30% of individuals worldwide. Also, according to the NIH, Chronic pain is favorably dominant among geriatric adults, associated with substantial suffering, disability, social solitariness, and higher expenditures and burden to health care systems. Thus, the growing geriatric population is contributing to the growth of the chronic pain segment. For example, according to WHO, the geriatric population accounted for 1 billion in 2020 and is predicted to reach 1.4 billion by 2030. Thus the data mentioned above indicate that the chronic pain type will dominate the global pain relief medication market

Geographical Analysis

North America oppresses the global pain relief medication market throughout the forecast period (2022-2029).

Owing to the high number of chronic disease cases and the presence of key market players, the North American pain relief medication market is assessed to grow at a high CAGR in the forecast period (2022-2029). Such as, according to the American cancer society estimations, in 2022, about 1.9 million new cancer cases will be analyzed, and around 609,360 cancer-caused deaths in the United States. Likewise, CDC anticipated that approximately 78 million U.S. adults will live with doctor-diagnosed arthritis in 2040, increasing the demand for the Pain Relief Medication analgesic. Similarly, the major key players holding a larger share of the market are U.S. based, such as Johnson & Johnson, Pfizer Inc., Purdue Pharma, Endo International, Mylan, Impax Laboratories and Indivior, contributing to the dominance of North America over the global Pain Relief Medication market. Therefore from the data mentioned above, it is anticipated that North America will hold most of the global pain relief medication market throughout the forecasted period (2022-2029).

Competitive Landscape

The pain relief medication market is moderately competitive since there is a growing demand for pain relief medication and local and global key players. Some key players are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline plc., Bristo-Meyers Squibb and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Merck & Co., and Cardinal Health Inc. These key players hold the market through acquisition, product launches, and collaborations. For instance, in July 2021, Venus Remedies Limited launched a consumer healthcare division that will offer various products for pain management.

Teva Pharmaceutical Industries Ltd.

Overview

Teva Pharmaceuticals was founded in 1901 in Jerusalem. It is today among the top 15 pharmaceutical companies worldwide. Teva has over 3600 medicines in its product portfolio, with 37,000 employees working globally and 53 production sites globally.

Product Portfolio:

Teva Pharmaceutical's product portfolio of pain relief medication has: Hydromorphone comes under the family of drugs known as opioid painkillers. It is employed to treat moderate-to-severe pain, such as pain after surgery.

The global pain relief medication market report would provide access to approximately 40 + market data tables, 45 + figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Growing Demand for Pain Relief Medication
      • 4.1.1.2. Growing Geriatric Population
    • 4.1.2. Restraints
      • 4.1.2.1. Availability of Other Options
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.1.2. Market Attractiveness Index, By Route of Administration
  • 7.2. Oral
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Injectable
  • 7.4. Topical

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 8.1.2. Market Attractiveness Index, By Type
  • 8.2. Acute
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Chronic

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacy
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Teva Pharmaceutical Industries Ltd.
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Pfizer Inc.
  • 12.3. Johnson & Johnson Services Inc.
  • 12.4. Bayer AG
  • 12.5. Sanofi S.A.
  • 12.6. GlaxoSmithKline plc.
  • 12.7. Bristo-Meyers Squibb and Company
  • 12.8. Mylan N.V.
  • 12.9. Merck & Co.
  • 12.10. Cardinal Health Inc.

LIST NOT EXHAUSTIVE

13. DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us